超声内镜引导胆道引流对比内镜逆行胰胆管造影用于恶性胆道梗阻初始姑息治疗的多中心随机临床试验
该多中心随机临床试验在韩国4家三级学术转诊中心纳入125例不可切除恶性远端胆道梗阻患者,随机分配至超声内镜引导胆道引流(EUS-BD)或内镜逆行胰胆管造影(ERCP)支架置入。EUS-BD技术成功率93.8%(60/64)非劣于ERCP的90.2%(55/61),临床成功率两组无显著差异,EUS-BD总体不良事件、再干预率更低且支架通畅率更高。
要点
- EUS-BD技术成功率93.8%(60/64)对ERCP 90.2%(55/61),非劣效检验P=0.003。
- EUS-BD总体不良事件6.3%对ERCP 19.7%(P=0.03),术后胰腺炎0对14.8%。
- EUS-BD再干预15.6%对ERCP 42.6%,支架通畅率85.1%对48.9%。
核心结论
- EUS-BD与ERCP在缓解恶性远端胆道梗阻方面技术成功率和临床成功率相当。
- EUS-BD观察到支架通畅时间显著更长、不良事件和再干预率更低、生活质量保持更好。
研究设计与样本
- 多中心随机临床试验,在韩国4家三级学术转诊中心进行随机分配。
- 纳入125例不可切除恶性远端胆道梗阻患者,随机分配至EUS-BD或ERCP。
主要发现
- 技术成功率EUS-BD 93.8%(60/64)对ERCP 90.2%(55/61),差值3.6%,95%单侧置信区间下限-4.4%,非劣效界值10%时P=0.003。
- 临床成功率EUS-BD 90.0%(54/60)对ERCP 94.5%(52/55),P=0.49。
- 总体不良事件EUS-BD 6.3%对ERCP 19.7%(P=0.03),术后胰腺炎EUS-BD 0对ERCP 14.8%。
- 再干预EUS-BD 15.6%对ERCP 42.6%,支架通畅率EUS-BD 85.1%对ERCP 48.9%。
- 术后12周EUS-BD较经乳头支架置入保持更好的生活质量。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: The goal of the study was to determine whether endoscopic ultrasound (EUS)-guided biliary drainage (EUS-BD) is comparable to conventional transpapillary stenting with endoscopic retrograde cholangiopancreatography (ERCP) in palliation of malignant distal biliary obstruction. Although ERCP for the palliation of malignant biliary obstruction is the standard of care, post-procedure pancreatitis and stent dysfunctions are not uncommon. While EUS-BD has garnered interest as a viable alternative when ERCP is impossible, its role as a primary palliation of malignant distal biliary obstruction is yet to be proven. METHODS: We performed random allocation to EUS-BD or ERCP in 125 patients with unresectable malignant distal biliary obstruction at four tertiary academic referral centers in South Korea. RESULTS: Technical success rates were 93.8% (60/64) for EUS-BD and 90.2% (55/61) for ERCP (difference 3.6%, 95% 1-sided confidence interval lower limit -4.4%, P = 0.003 for noninferiority margin of 10%). Clinical success rates were 90.0% (54/60) in EUS-BD and 94.5% (52/55) in ERCP (P = 0.49). Lower rates of overall adverse events (6.3% vs 19.7%, P = 0.03) including post-procedure pancreatitis (0 vs 14.8%), reintervention (15.6% vs 42.6%), and higher rate of stent patency (85.1% vs 48.9%) were observed with EUS-BD. EUS-BD was also associated with more preserved quality of life (QOL) than transpapillary stenting after 12 weeks of the procedure. CONCLUSIONS: This study demonstrated comparable technical and clinical success rates between EUS-BD and ERCP in relief malignant distal biliary obstruction. Substantially longer duration of patency coupled with lower rates of adverse events and reintervention, and more preserved QOL were observed with EUS-BD (cris.nih.go.kr, Identifier: KCT0001396, https://cris.nih.go.kr/cris/search/search_result_st01_en.jsp?seq=9716<ype=&rtype= ).
引用
- Paik WH, Lee TH, Park DH, et al. EUS-Guided Biliary Drainage Versus ERCP for the Primary Palliation of Malignant Biliary Obstruction: A Multicenter Randomized Clinical Trial. Am J Gastroenterol. 2018. PMID: 29961772. doi:10.1038/s41395-018-0122-8
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。